Brittney M Snyder1, Rebecca J Baer2, Scott P Oltman3, Jennifer G Robinson1, Patrick J Breheny4, Audrey F Saftlas1, Wei Bao1, Andrea L Greiner5, Knute D Carter4, Larry Rand6, Laura L Jelliffe-Pawlowski3, Kelli K Ryckman7. 1. Department of Epidemiology, University of Iowa College of Public Health, Iowa City, IA, United States. 2. Department of Pediatrics, University of California San Diego, La Jolla, CA, United States; California Preterm Birth Initiative, University of California San Francisco, San Francisco, CA, United States. 3. California Preterm Birth Initiative, University of California San Francisco, San Francisco, CA, United States; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, United States. 4. Department of Biostatistics, University of Iowa College of Public Health, Iowa City, IA, United States. 5. Department of Obstetrics and Gynecology, University of Iowa Carver College of Medicine, Iowa City, IA, United States. 6. California Preterm Birth Initiative, University of California San Francisco, San Francisco, CA, United States; Department of Obstetrics, Gynecology & Reproductive Sciences, University of California San Francisco, San Francisco, CA, United States. 7. Department of Epidemiology, University of Iowa College of Public Health, Iowa City, IA, United States; Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, IA, United States. Electronic address: kelli-ryckman@uiowa.edu.
Abstract
AIMS: To evaluate the clinical utility of first and second trimester prenatal screening biomarkers for early pregnancy prediction of gestational diabetes mellitus (GDM) risk in nulliparous women. METHODS: We conducted a population-based cohort study of nulliparous women participating in the California Prenatal Screening Program from 2009 to 2011 (n = 105,379). GDM was ascertained from hospital discharge records or birth certificates. Models including maternal characteristics and prenatal screening biomarkers were developed and validated. Risk stratification and reclassification were performed to assess clinical utility of the biomarkers. RESULTS: Decreased levels of first trimester pregnancy-associated plasma protein A (PAPP-A) and increased levels of second trimester unconjugated estriol (uE3) and dimeric inhibin A (INH) were associated with GDM. The addition of PAPP-A only and PAPP-A, uE3, and INH to maternal characteristics resulted in small, yet significant, increases in area under the receiver operating characteristic curve (AUC) (maternal characteristics only: AUC 0.714 (95% CI 0.703-0.724), maternal characteristics + PAPP-A: AUC 0.718 (95% CI 0.707-0.728), maternal characteristics + PAPP-A, uE3, and INH: AUC 0.722 (0.712-0.733)); however, no net improvement in classification was observed. CONCLUSIONS: PAPP-A, uE3, and INH have limited clinical utility for prediction of GDM risk in nulliparous women. Utility of other readily accessible clinical biomarkers in predicting GDM risk warrants further investigation.
AIMS: To evaluate the clinical utility of first and second trimester prenatal screening biomarkers for early pregnancy prediction of gestational diabetes mellitus (GDM) risk in nulliparous women. METHODS: We conducted a population-based cohort study of nulliparous women participating in the California Prenatal Screening Program from 2009 to 2011 (n = 105,379). GDM was ascertained from hospital discharge records or birth certificates. Models including maternal characteristics and prenatal screening biomarkers were developed and validated. Risk stratification and reclassification were performed to assess clinical utility of the biomarkers. RESULTS: Decreased levels of first trimester pregnancy-associated plasma protein A (PAPP-A) and increased levels of second trimester unconjugated estriol (uE3) and dimeric inhibin A (INH) were associated with GDM. The addition of PAPP-A only and PAPP-A, uE3, and INH to maternal characteristics resulted in small, yet significant, increases in area under the receiver operating characteristic curve (AUC) (maternal characteristics only: AUC 0.714 (95% CI 0.703-0.724), maternal characteristics + PAPP-A: AUC 0.718 (95% CI 0.707-0.728), maternal characteristics + PAPP-A, uE3, and INH: AUC 0.722 (0.712-0.733)); however, no net improvement in classification was observed. CONCLUSIONS:PAPP-A, uE3, and INH have limited clinical utility for prediction of GDM risk in nulliparous women. Utility of other readily accessible clinical biomarkers in predicting GDM risk warrants further investigation.
Authors: L L Jelliffe-Pawlowski; R J Baer; Y J Blumenfeld; K K Ryckman; H M O'Brodovich; J B Gould; M L Druzin; Y Y El-Sayed; D J Lyell; D K Stevenson; G M Shaw; R J Currier Journal: BJOG Date: 2015-06-26 Impact factor: 6.531
Authors: Ewout W Steyerberg; Andrew J Vickers; Nancy R Cook; Thomas Gerds; Mithat Gonen; Nancy Obuchowski; Michael J Pencina; Michael W Kattan Journal: Epidemiology Date: 2010-01 Impact factor: 4.822
Authors: Rebecca J Baer; Mary E Norton; Gary M Shaw; Monica C Flessel; Sara Goldman; Robert J Currier; Laura L Jelliffe-Pawlowski Journal: Am J Obstet Gynecol Date: 2014-06-17 Impact factor: 8.661
Authors: Robyn A North; Lesley M E McCowan; Gustaaf A Dekker; Lucilla Poston; Eliza H Y Chan; Alistair W Stewart; Michael A Black; Rennae S Taylor; James J Walker; Philip N Baker; Louise C Kenny Journal: BMJ Date: 2011-04-07
Authors: Brittney M Donovan; Patrick J Breheny; Jennifer G Robinson; Rebecca J Baer; Audrey F Saftlas; Wei Bao; Andrea L Greiner; Knute D Carter; Scott P Oltman; Larry Rand; Laura L Jelliffe-Pawlowski; Kelli K Ryckman Journal: PLoS One Date: 2019-04-12 Impact factor: 3.240
Authors: Nicholas P Deputy; Shin Y Kim; Elizabeth J Conrey; Kai McKeever Bullard Journal: MMWR Morb Mortal Wkly Rep Date: 2018-11-02 Impact factor: 17.586